Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

DISEASE CHARACTERISTICS: Histologically or cytologically confirmed small cell lung cancer (SCLC) Must have received at least one prior course of standard chemotherapy and, if indicated, up to 6,900 cGy of thoracic radiotherapy Patients who received prior radiotherapy must show evidence of progressive disease Patients who received no prior radiotherapy to the primary tumor must show evidence of stable or progressive disease Measurable disease Must have evidence of carcinoembryonic antigen (CEA) production or expression documented by one of the following: Serum CEA at least 10 ng/mL Positive immunohistology of either the primary tumor or a metastasis with CEA specific monoclonal antibody Must have unilateral bone marrow biopsy with less than 25% tumor involvement No known, active brain metastases PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70-100% ECOG 0-2 Life expectancy: At least 3 months Hematopoietic: WBC at least 3,000/mm^3 Granulocyte count at least 1,500/mm^3 Platelet count at least 100,000/mm^3 Hepatic: Bilirubin no greater than 2 mg/dL AST no greater than 2 times upper limit of normal (ULN) No hepatitis B or C No other serious liver abnormality Renal: Creatinine no greater than 1.5 times ULN No urinary incontinence Cardiovascular: Ejection fraction at least 50% Pulmonary: FEV_1 and FVC at least 60% DLCO at least 50% predicted Other: No severe anorexia, nausea, or vomiting No other significant medical problems No prisoners No reactivity to humanized MN-14 (in patients with prior exposure to chimeric or humanized antibody) HIV negative No active HIV-related disease Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during and for at least 3 months following study participation PRIOR CONCURRENT THERAPY: Biologic therapy: See Chemotherapy No concurrent growth factors (e.g., filgrastim [G-CSF]) Chemotherapy: See Disease Characteristics At least 4 weeks since prior chemotherapy No prior high dose chemotherapy with stem cell transplantation Endocrine therapy: Not specified Radiotherapy: See Disease Characteristics At least 4 weeks since prior radiotherapy Prior radiotherapy to less than 30% of red marrow (including standard chest x-ray for limited stage SCLC) allowed Surgery: At least 4 weeks since prior major surgery